Brief: Dermapharm Holding: FY Adjusted Group EBITDA Up At 3-7%

Dermapharm Holding SE

29/03/2022 06:37

March 29 (Reuters) - DERMAPHARM HOLDING SE  DMPG.DE :
    * CONTINUOUS GROWTH OF GROUP REVENUES AND ADJUSTED GROUP
EBITDA IN
2022
    * FY GROUP REVENUE TO GROW BY 10% TO 13% YEAR-ON-YEAR
    * INCREASE IN FY ADJUSTED GROUP EBITDA OF 3% TO 7 % COMPARED
TO
PREVIOUS YEAR
    * EXPANSION OF VACCINE COOPERATION WITH BIONTECH SE
    * SOLID ORGANIC GROWTH IN CORE "BRANDED PHARMACEUTICALS"
BUSINESS
    * ADDITIONAL REVENUE AND EARNINGS CONTRIBUTION FROM
INTEGRATION OF
CANNABIS BUSINESS

Source text for Eikon:  ID:nEQ1fDxmca 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))